ReShape Lifesciences Inc. (RSLS)
- Previous Close
0.3619 - Open
0.3500 - Bid --
- Ask --
- Day's Range
0.3296 - 0.3524 - 52 Week Range
0.3000 - 29.0000 - Volume
1,226,116 - Avg. Volume
15,934,539 - Market Cap (intraday)
3.841M - Beta (5Y Monthly) 1.92
- PE Ratio (TTM)
-- - EPS (TTM)
-13.8300 - Earnings Date May 13, 2025 - May 19, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
ReShape Lifesciences Inc. provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus. It is involved in developing ReShape Obalon Balloon System, consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and ReShape Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in Irvine, California.
www.reshapelifesciences.comRecent News: RSLS
View More
Performance Overview: RSLS
Trailing total returns as of 4/29/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RSLS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RSLS
View MoreValuation Measures
Market Cap
4.08M
Enterprise Value
4.35M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.02
Price/Book (mrq)
--
Enterprise Value/Revenue
0.54
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-89.06%
Return on Assets (ttm)
-53.93%
Return on Equity (ttm)
-222.46%
Revenue (ttm)
8.01M
Net Income Avi to Common (ttm)
-7.13M
Diluted EPS (ttm)
-13.8300
Balance Sheet and Cash Flow
Total Cash (mrq)
693k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-1.63M